Loading…
Liquidia Corp
Liquidia Corp (LQDA) is listed on NASDAQ and classified in Drug Manufacturers - Specialty & Generic, part of the Healthcare sector. It is headquartered in Morrisville, United States and has 216 employees. The company is worth $3.55B and trades at 28.0x its earnings of the last twelve months; the median for its sector is 24.3x. Revenue was $158.32M in fiscal 2025, up 1031.2% from the year before. It reported a net loss of $68.92M. The share price is 57.6% below its 52-week high of $93.61. 3 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Two Sigma (Two Sigma Investments), at $21.27M. In that quarter, 2 of them opened or added to the position and 1 reduced it. Over the last 30 days, company insiders sold $9.32M of its stock on the open market and bought none.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Major managers that reported this stock in their latest 13F.
▲ +727.7% over 5Y.
today you would have $9,160.00▲ +816.0%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 7 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Year-end price | $34.49 | $11.76 | $12.03 | $6.37 | $4.87 | $2.95 | $4.28 | |
| P/S | 25.9x | 19.2x | 71.7x | 52.3x | 25.9x | 19.9x | 172.8x | 15.0x |
| P/B | 4.6x | 67.9x | 12.6x | 19.3x | 4.6x | 3.9x | 1.8x | 3.5x |
| EPS |
Seven formulas applied to the reported numbers, each with its assumption next to the result. None of them predicts a price.
Square root of 22.5 × earnings × book value. Blind to intangibles, so it undervalues software and brands.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Median P/E of 24.3 among peers in the sector.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| XENEXenon Pharmaceuticals Inc. | $36.50 | — | 2.8x | 0.00% | -43.62% | $3.53B |
| CDNACareDx, Inc. | $69.16 | 33.3x | 8.4x | 0.00% | 29.49% | $3.58B |
| AMLXAmylyx Pharmaceuticals, Inc. | $28.57 | — | 13.3x | 0.00% | -74.73% | $3.59B |
| ACADAcadia Pharmaceuticals Inc | $20.31 |
| -$0.80 |
| -$1.63 |
| -$1.21 |
| -$0.67 |
| -$0.70 |
| -$1.76 |
| -$2.57 |
| Profit margin | -448.89% | -43.53% | -916.63% | -448.89% | -257.39% | -269.03% | -8080.11% | -589.48% |
| ROE | -136.16% | -154.03% | -161.62% | -165.99% | -45.36% | -52.98% | -84.07% | -136.16% |
Median of the years shown; P/E years above 200x are left out.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
The average of the method families that answered, not of the seven numbers: four of the seven start from the same earnings per share.
2 methods answered, across 1 families.
Room for errors in the reported numbers.
-46.0% from the average.
Models, not forecasts, and not investment advice. How each formula works →
| 9.1x |
| 2.7x |
| 0.00% |
| 35.74% |
| $3.5B |
| OGNOrganon & Co. | $13.75 | 17.6x | 3.6x | 0.58% | 24.04% | $3.61B |
| IDYAIDEAYA Biosciences, Inc. | $36.12 | — | 2.9x | 0.00% | -16.22% | $3.49B |